OncoMatch/Clinical Trials/NCT04680260
OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer
Is NCT04680260 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for colorectal cancer.
A study investigating if analysis of circulating tumor DNA (ctDNA) can guide adjuvant treatment in patients with advanced colorectal cancer (CRC)
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
absolute neutrophil count ≥1.5x109/l and thrombocytes ≥ 100x109/l
Kidney function
calculated or measured renal glomerular filtration rate at least 30 ml/min
Liver function
bilirubin ≤ 1.5 x upper normal value and alanine aminotransferase ≤ 3 x upper normal value
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify